Top View
- Leading Article Gut: First Published As 10.1136/Gut.39.6.784 on 1 December 1996
- MTUS DRUG-LIST-V3-Addendum-One-Effective 10012018
- Prior Authorization PDL Implementation Schedule
- Modernized Reference Drug Program Histamine2 Receptor Blockers (H2 Blockers)
- In Vivo Pharmacodynamic Interaction Between Pipecuronium and Certain H2 Blockers
- The Association Between Ranitidine Use and Gastrointestinal Cancers
- Cimetidine Use and Risk of Prostate and Breast Cancer
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to Nqtls, by Delivery System
- Potentially Harmful Drugs in the Elderly: Beers List and More
- (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
- D Rug U Tilization R Eview B Oard
- Preferred Drug List (PDL)
- Lafutidine 10 Mg Versus Rabeprazole 20 Mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: a Randomized, Multicentric Trial
- Consultation: Cimetidine, Famotidine, Nizatidine and Ranitidine
- Preferred Drug List
- (CD-P-PH/PHO) Report Classification/Justifica
- YAMANOUCHI PHARM. CO. V. DANBURY PHAR. Yamamouchi’S Patent
- 2020 Ranitidine and Other Histamine-H2
- Laryngopharyngeal Reflux Disease
- Pharmaceutical Combinations of Rivaroxaban and H2-Receptor Antagonists
- Lafutidine Changes Levels of Somatostatin, Calcitonin Gene-Related Peptide, and Secretin in Human Plasma
- Association of Gastric Acid Suppression with Recurrent Clostridium Difficile Infection: a Systematic Review and Meta-Analysis
- Laboratory Analysis of Ranitidine and Nizatidine Products
- The Effects of Nizatidine on Transient Lower Esophageal Sphincter Relaxations (Tlesrs) and Acid Reflux in Healthy Subjects
- Metopimazine/Nizatidine 1751 Ataxia, Confusion, Disorientation, Dizziness, Euphoria, Dysphoria, Little Effect on the Metabolism of Other Drugs
- Non-Preferred Drug List (NPDL)
- Relationship Between Histamine2-Receptor Antagonist Medications and Risk of Invasive Breast Cancer
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Apple Health Medicaid: Fee-For-Service Preferred Drug List
- United States Patent (19) 11 Patent Number: 4,824,664 Tarral Et Al
- H2-Antagonists (Cimetidine, Famotidine and Nizatidine)
- Therapeutic Drug Class
- ICD-9) Used in This Study
- UMP (Wsrxs) Preferred Drug List (PDL) 2021
- AXID® (Nizatidine) Capsules, USP ®
- Drug Interactions of H2-Receptor Antagonists Involving Cytochrome